as of 12-17-2025 1:52pm EST
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | NATICK |
| Market Cap: | 15.4M | IPO Year: | N/A |
| Target Price: | $9.25 | AVG Volume (30 days): | 113.0K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.02 - $16.81 | Next Earning Date: | 11-12-2025 |
| Revenue: | $17,208,000 | Revenue Growth: | -50.49% |
| Revenue Growth (this year): | -53.82% | Revenue Growth (next year): | 9.02% |
See how ALUR stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "ALUR Allurion Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.